Vandetanib for Differentiated Thyroid Cancer

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.

Clinical Pearls

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses research into vandetanib for the treatment of patients with differentiated thyroid cancer.

  • A phase II study randomized 145 patients with locally advanced or metastatic differentiated thyroid carcinoma to vandetanib or placebo
  • This study saw fewer full responses than in the DECISION trial, though progression-free survival was 11.1 months compared with 5.9 months in the vandetanib and placebo arm, respectively.
  • The vast majority of patients treated with sorafenib will need a second-line therapy, reinforcing the need for an efficacious agent in this space.